- Ceritinib - a new hope for patients with ALK-positive translocation of non-small-cell lung cancers +12015 | Faculty of Medicine in Pilsen
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Advanced lung cancer as chronic disease2015 | Faculty of Medicine in Pilsen
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma2018 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- ALK-driven non-small cell lung cancer: Prevention, prophylaxis, and treatment of brain metastases2021 | Faculty of Medicine in Pilsen
- Non-small cell lung cancer with ALK and R0S1 genes rearregement2018 | Faculty of Medicine in Pilsen
- Strategie léčby ALK-pozitivního NSCLC2018 | Second Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Současné možnosti léčby ALK-pozitivního NSCLC2021 | First Faculty of Medicine
- Drug-induced pericarditis2022 | Publication without faculty affiliation
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Management of advanced non-small cell lung cancer +12015 | First Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2019 | Second Faculty of Medicine
- New alternatives and approaches in the treatment of advanced non-small cell lung cancer2015 | Faculty of Medicine in Pilsen
